HC Wainwright set a $12.00 price target on Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note published on Friday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Guggenheim began coverage on shares of Foamix Pharmaceuticals in a research note on Tuesday, December 5th. They issued a buy rating and a $8.00 price objective for the company. Zacks Investment Research raised shares of Foamix Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, November 29th.

Shares of Foamix Pharmaceuticals (FOMX) traded down $0.36 during trading on Friday, hitting $6.28. 129,430 shares of the stock were exchanged, compared to its average volume of 84,826. Foamix Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $11.27. The stock has a market cap of $248.56, a PE ratio of -3.90 and a beta of 1.62.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.90 million. During the same period last year, the company posted ($0.19) EPS. Foamix Pharmaceuticals’s revenue for the quarter was down 64.6% on a year-over-year basis. analysts anticipate that Foamix Pharmaceuticals will post -0.95 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. AXA boosted its stake in shares of Foamix Pharmaceuticals by 14.1% in the 2nd quarter. AXA now owns 942,735 shares of the specialty pharmaceutical company’s stock valued at $4,374,000 after purchasing an additional 116,298 shares in the last quarter. DAFNA Capital Management LLC raised its holdings in Foamix Pharmaceuticals by 9.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 355,667 shares of the specialty pharmaceutical company’s stock valued at $1,650,000 after buying an additional 30,000 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Foamix Pharmaceuticals by 38.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock valued at $2,528,000 after buying an additional 151,849 shares during the last quarter. PDT Partners LLC bought a new stake in Foamix Pharmaceuticals during the 2nd quarter valued at $304,000. Finally, UBS Asset Management Americas Inc. raised its holdings in Foamix Pharmaceuticals by 1.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock valued at $493,000 after buying an additional 1,633 shares during the last quarter. 57.43% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/06/foamix-pharmaceuticals-fomx-given-a-12-00-price-target-by-hc-wainwright-analysts.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Stock Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related stocks with our FREE daily email newsletter.